Diagnostic marker

• US 20060063199A1
• Filed: 11/23/2004
• Published: 03/23/2006
• Est. Priority Date: 09/21/2004
• Status: Abandoned Application

• Current Assignee: Nour Heart, Inc.
• Original Assignee: Nour Heart, Inc.
• Inventors: Elgebaly, Salwa A., Sheard, Paul
• Application Number:
  US10/994,521
• Publication Number:
  US 20060063199A1
• Time in Patent Office: Days
• US Class Current: 435/7.100
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: G01N 2800/324 Coronary artery diseases, e.g. angina pectoris, myocardial infarction
• CPC Class Codes: G01N 33/6887 from muscle, cartilage or connective tissue

Abstract

An inflammatory peptide can be a marker for cardiac ischemia.

Claims

1. A method of detecting cardiac ischemia in a patient comprising:

obtaining a sample from a patient suspected of suffering cardiac ischemia or other cardiac event, and contacting the sample with an antibody that recognizes Nourin-1 to detect a level of Nourin-1; and

detecting in a sample taken from the patient a level of a first marker associated with lipid oxidation, oxidative stress, or myocardial stretch.

2. The method of claim 1, wherein the first marker is selected from the group consisting of myeloperoxidase, choline, BNP, N-terminal proBNP, N-terminal proANP, fatty acid binding protein, total creatine kinase, creatine kinase isoforms, myosin light chains, oxidized-LDL, MDA-modified LDL, minimally modified LDL, oxygen-regulated peptide 150, a urotensin, a urotensin-related peptide, interleukin-8, complement component C5a, a metallic matrix protease, monocytes chemoattractant peptides 1, IL-18, glutathione peroxidase-1, and white blood cell count.

3. The method of claim 1, wherein the patient is a mammal.

4. The method of claim 3, wherein the patient is a human.

5. The method of claim 4, wherein the sample includes blood, blood plasma or serum.

6. The method of claim 4, wherein the sample includes interstitial fluid, saliva, cardiac tissue, or urine.

7. The method of claim 4, further comprising recording an electrocardiogram of the patient.

8. The method of claim 1, further comprising detecting a level of a second marker associated with cardiac ischemia, cardiac necrosis, lipid oxidation, oxidative stress, myocardial stretch, inflammation, plaque rupture, thrombus formation, platelet aggregation or activation, myocardial conduction, or myocardial infarction, in a sample taken from the patient.

9. A method of detecting cardiac ischemia in a mammal comprising:

detecting a level of Nourin-1 in the mammal; and

detecting a level of a first marker associated with lipid oxidation, oxidative stress, or myocardial stretch in the mammal.

10. The method of claim 9, wherein the first marker is selected from the group consisting of myeloperoxidase, choline, BNP, N-terminal proBNP, N-terminal proANP, fatty acid binding protein, total creatine kinase, creatine kinase isoforms, myosin light chains, oxidized-LDL, MDA-modified LDL, minimally modified LDL, oxygen-regulated peptide 150, a urotensin, a urotensin-related peptide, interleukin-8, complement component C5a, a metallic matrix protease, monocytes chemoattractant peptides 1, IL-18, glutathione peroxidase-1, and white blood cell count.

11. The method of claim 10, wherein the patient is a human.

12. The method of claim 9, wherein detecting a level of Nourin-1 includes contacting a sample obtained from the mammal with an antibody that recognizes Nourin-1.

13. The method of claim 12, wherein the sample includes blood, blood plasma, serum interstitial fluid, saliva, cardiac tissue, or urine.

14. The method of claim 9, further comprising recording an electrocardiogram of the patient.

15. The method of claim 9, further comprising detecting a level of a second marker associated with cardiac ischemia, cardiac necrosis, lipid oxidation, oxidative stress, myocardial stretch, inflammation, plaque rupture, thrombus formation, platelet aggregation or activation, myocardial conduction, or myocardial infarction, in the mammal.

16. A method of detecting cardiac ischemia in a mammal comprising:

detecting a level of Nourin-1 in the mammal;

detecting a level of a first marker associated with lipid oxidation, oxidative stress, or myocardial stretch in the mammal; and

detecting a level of a second marker associated with cardiac ischemia, cardiac necrosis, lipid oxidation, oxidative stress, myocardial stretch, inflammation, plaque rupture, thrombus formation, platelet aggregation or activation, myocardial conduction, or myocardial infarction, in the mammal.

17. The method of claim 16, wherein the first marker is selected from the group consisting of myeloperoxidase, choline, BNP, N-terminal proBNP, N-terminal proANP, fatty acid binding protein, total creatine kinase, creatine kinase isoforms, myosin light chains, oxidized-LDL, MDA-modified LDL, minimally modified LDL, oxygen-regulated peptide 150, interleukin-8, complement component C5a, a metallic matrix protease, monocytes chemoattractant peptides 1, IL-18, glutathione peroxidase-1, and white blood cell count.

18. The method of claim 17, wherein the patient is a human.

19. The method of claim 17, wherein detecting a level of Nourin-1 includes contacting a sample obtained from the mammal with an antibody that recognizes Nourin-1.

20. The method of claim 17, wherein the sample includes blood, blood plasma, serum interstitial fluid, saliva, cardiac tissue, or urine.